Title: Validation of self-collected buccal swab and saliva as a diagnostic tool for COVID-19

## **Authors:**

Chee Wai Ku<sup>1,2\*</sup>, Durai Shivani<sup>1,\*</sup>, Jacqueline Q T Kwan<sup>3</sup>, See Ling Loy<sup>2,4</sup>, Christina Erwin<sup>2</sup>, Karrie K K Ko<sup>2,3,5,6</sup>, Xiang Wen Ng<sup>4</sup>, Lynette Oon<sup>6</sup>, Koh Cheng Thoon<sup>7</sup>, Shirin Kalimuddin<sup>8,9, #</sup>, Jerry KY Chan<sup>2,4, #</sup>

### **Affiliations:**

<sup>1</sup>Department of Obstetrics and Gynaecology, KK Women's and Children's Hospital, 100 Bukit Timah Road, 229899, Singapore.

<sup>2</sup>Academic Program in Obstetrics and Gynaecology, Duke-NUS Medical School, Singapore, Singapore 169857

<sup>3</sup>Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

<sup>4</sup>Department of Reproductive Medicine, KK Women's and Children's Hospital, Singapore 229899, Singapore

<sup>5</sup>Department of Microbiology, Singapore General Hospital, Singapore.

<sup>6</sup>Department of Molecular Pathology, Singapore General Hospital, Singapore.

<sup>7</sup>Department of Paediatrics, KK Women's and Children's Hospital, Singapore, Singapore.

<sup>8</sup>Department of Infectious Diseases, Singapore General Hospital, Singapore.

<sup>9</sup>Programme in Emerging Infectious Diseases, Duke-NUS Medical School, 169857, Singapore.

\* Denotes co-first authors

# Denotes co-last authors

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

All rights reserved.	No reuse allowe	ed without permission.
----------------------	-----------------	------------------------

Co	rre	sno	ndin	σΔ	uth	٥r٠
CU	יו וי	วมบ	HUHH	2 74	uui	uı.

Jerry Kok Yen Chan

Address: Department of Reproductive Medicine, KK Women's and Children's Hospital, 100, Bukit

Timah

Email: jerrychan@duke-nus.edu.sg

Phone: 65-81253639

# **Running title:**

Buccal & Saliva tests for SARS-CoV-2

## **Keywords:**

SARS-CoV-2, COVID-19, Diagnostic tests, Buccal swab, Saliva test

**ABSTRACT** 

Background: Effective management of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-

2) requires large-scale testing. Collection of nasopharyngeal swab (NPS) by healthcare workers (HCW)

is currently used to diagnose SARS-CoV-2, which increases the risk of transmission to HCWs. Self-

administered saliva and buccal swabs are convenient, painless and safe alternative sample collection

methods.

Methods: A cross-sectional single centre study was conducted on 42 participants who were tested

positive for SARS-CoV-2 via NPS within the past 7 days. A self-collected saliva and buccal swab and a

HCW-collected NPS were obtained. Real-time polymerase chain reaction (RT-PCR) was performed and

cycle threshold (CT) values were obtained. Positive percent agreement (PPA), negative percent

agreement (NPA) and overall agreement (OA) were calculated for saliva and buccal swabs, as

compared with NPS.

Results: Among the 42 participants, 73.8% (31/42) tested positive via any one of the 3 tests. With

reference to NPS, the saliva test had PPA 66.7%, NPA 91.7% and OA 69.0%. The buccal swab had PPA

56.7%, NPA 100% and OA 73.8%. Presence of symptoms improved diagnostic accuracy. There was no

statistically significant association between CT values and duration of symptom onset within the first

12 days of symptoms for all three modalities.

Conclusion: Self-collected saliva tests and buccal swabs have only moderate agreement with HCW-

collected NPS swabs. Primary screening for SARS-CoV-2 may be performed with a saliva test or buccal

swab, with a negative test warranting a confirmatory NPS to avoid false negatives. This combined

strategy minimizes discomfort and reduces the risk of spread to the community and HCWs.

**BACKGROUND** 

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the causative agent of Coronavirus

Disease 2019 (COVID-19), was first identified in December 2019 [1]. In March 2020, COVID-19 was

declared a pandemic by the World Health Organisation.

One of the main reasons for the high rate of transmission is the significant proportion of asymptomatic

but infective carriers. Hence safe and effective detection of asymptomatic COVID-19 patients through

appropriate large-scale testing is of paramount importance.

As the clinical symptoms COVID-19 patients experience are often nonspecific, the current method of

detection relies heavily on molecular techniques. It is recommended that samples for testing are

obtained from the upper respiratory tract rather than lower respiratory tract [2]. These include

nasopharyngeal swabs (NPS), the current standard test, as well as oropharyngeal swabs, saliva

specimen, and nasal aspirates.

The accuracy of COVID-19 detection varies according to the viral load in the different respiratory tract

samples. In the first 14 days after onset of illness, SARS-CoV-2 was most reliably detected in sputum

samples, which contained the highest viral load, followed by nasal swabs [3, 4]. There are several

disadvantages of the NPS, which is considered the current standard test "gold-standard" test in most

settings. Firstly, NPS can only be performed by trained HCWs. The patient needs to travel to the

swabbing facility which increases the risk of community spread. Secondly, to perform the swab, the

medical staff must be in close contact with the patient. Coughing or retching by the patient could

produce a large number of aerosolised droplets, increasing the risk of HCW transmission [5]. Thirdly,

this increases the burden on the currently heavily strained healthcare system by diverting a lot of

resources to the diagnosis of SARS-CoV-2. Furthermore, a significant proportion of suspect cases who

reside in the community are asymptomatic and are only called up for testing as a result of contact

tracing from a confirmed COVID-19 case and hence are unlikely to present for testing. Hence, our

group seeks to validate diagnostic tests which can be performed by the patient at home, and if

validated, may have comparable concordance to NPS.

In instances where an NPS is not possible, the Centers for Disease Control and Prevention (CDC) and

the Food & Drug Administration (FDA) recommend a HCW-collected oropharyngeal specimen as other

alternatives. Indeed, active viral replication in the upper respiratory tract of young to middle-aged

patients with mild cases of COVID-19 has been demonstrated previously, with peak viral shedding

during the first week of symptoms [6]. There is also emerging evidence to suggest that supervised self-

collected oral fluid specimens perform similarly to HCW-collected NPS specimens for the detection of

SARS-CoV-2 infection [7].

In order to validate the use of buccal swabs and saliva specimen as alternative diagnostic tests for

SARS-CoV-2, our group performed a cross-sectional study of NPS, self-collected buccal swabs and

saliva specimens collected concurrently in order to determine the positive percent agreement (PPA),

negative percent agreement (NPA), overall agreement (OA), positive and negative predictive values.

The advantage of self-collected buccal swabs or saliva specimen is two-fold, 1) facilitates specimen

collection without patients leaving their home, thus improving compliance and ease of collection, and

2) reduces the risk of community spread and transmission to HCWs. This would revolutionize the

management of SARS-CoV-2, where suspect cases can send in a specimen for testing without

breaching quarantine notice, and thus increase detection rates without compromising the safety of

others.

**METHODS** 

**Setting and participants** 

A cross-sectional single centre study was conducted on 42 individuals who were previously tested

positive for SARS-CoV-2 via NPS within the past 7 days, and who were isolated at the Singapore

General Hospital (SGH). SGH is the largest tertiary hospital in Singapore and is one of the main referral

hospitals for treating COVID-19 patients.

The inclusion criteria were participants diagnosed with SARS-CoV-2 infection by NPS, between the

ages of 21-80 years. Patients who were unable to produce oral secretions for self-collection were

excluded from the study. Written informed consent was obtained. This study was approved by the

institution's ethics review board (CIRB Ref No 2020/2655).

Demographic, clinical data collection and survey on patient experience

Sociodemographic data and symptoms at time of sampling were obtained via a questionnaire

administered by a study team member, and through review of medical records. After sample

collection was complete, the patient's experience was surveyed. They were asked to select the test

that best fit each of the following qualities: 1) comfort 2) convenience and 3) personal preference.

Sample collection and processing

A saliva, buccal and NPS sample was obtained from each participant in that order. For the saliva

specimen, participants were asked to cough deeply five times and pool saliva in their mouth for 1-2

minutes prior to collection, and gently spit 1-2 mL of saliva into a 60 mL sterile closed-top plastic

collection container (BMH.921406, Biomedia, Singapore). Subsequently, for the buccal sample,

participants were asked to pool any phlegm or secretions in their mouth, rub the swab (300264,

Deltalab, Spain) on both cheeks, above and below the tongue, both gums, and on the hard palate for

a total of 20 seconds to ensure the swab was saturated with oral fluid. The swab was then placed in

the tube with the lid secured. Finally, the NPS (MSC-96000-ST, Miraclean, China) was collected by a

trained HCW for all patients, as per standard hospital protocol [8]. All swabs were processed in 1ml of

lysis buffer (Cobas Omni Lysis Reagent, P/N 06997538190) and in-house RT-PCR was performed on all

specimens based on protocol by Corman et al [9]. The results for SARS-CoV-2, including the E-gene

cycle threshold (CT) values, were correlated to that for the NPS. All signals that crossed the detection

threshold were considered a positive test.

Statistical analysis

Independent t-test or Mann-Whitney test was applied to continuous variables as appropriate, and

Fisher's exact test was applied to categorical variables. Results of the saliva and buccal swabs were

individually compared to the NPS and the positive percentage agreement (PPA), negative percentage

agreement (NPA), overall agreement (OA), positive predictive values (PPV) and negative predictive

values (NPV) were calculated. CT values between the saliva and buccal swabs with NPS were analysed

with the paired t-test. Statistical analyses were conducted using SPSS Statistics Version 20.0 (IBM Corp,

Armonk, NY, USA).

**RESULTS** 

All the patients who met the inclusion criteria were recruited. Among 42 participants who previously

tested positive for SARS-CoV-2 via a nasopharyngeal swab (NPS) within the preceding 7 days, 73.8%

(31/42) tested positive via any one of the 3 swab tests. Table 1 shows the baseline demographics

between those who tested positive or negative, for the three diagnostic tests for SARS-CoV-2, namely

NPS, buccal and saliva (Table 1). Participants who remained NPS positive at the time of study

recruitment were younger, and more likely to be symptomatic (Table 1). The survey of participant

experience showed that 59.5% (25/42) participants ranked the buccal swab as the most preferred,

most convenient, as well as most comfortable to collect. A total of 40.5% (17/42) participants chose

the saliva test as the most preferred, convenient, and comfortable means for first-line SARS-CoV-2

testing. Only one participant ranked NPS as most preferable (1/42), while none of the them felt that

it was convenient or comfortable.

The incidence of SARS-CoV-2 in this cohort as diagnosed using NPS was 71.4% (n=30/42). With

reference to the NPS, the buccal swab had a PPA of 56.7%, NPA of 100%, OA of 73.8%, PPV of 100%

and NPV of 48% (Table 2A). Viral load was lower in the buccal specimen, with the mean CT value for

the buccal swab being higher than NPS (27.19  $\pm$  2.48 vs 21.66  $\pm$  5.60, p < 0.001) (Figure 1A). With

reference to the NPS, the saliva sample had a PPA of 66.7%, NPA of 91.7%, OA of 69.0%, PPV of 95.2%

and NPV of 52.4% (Table 2B). There was no difference in CT values between saliva and NPS specimens

 $(25.77 \pm 5.60 \text{ vs } 22.95 \pm 6.03, p = 0.057)$ , suggesting a similar viral load in both samples (Figure 1B).

Presence of symptoms at the time of swab collection was associated with better diagnostic accuracy.

53.3% of symptomatic participants tested positive by both NPS and buccal swab (p = 0.017), while

63.3% were positive by both NPS and saliva sample (p = 0.004) (Table 3). There was no statistically

significant association between CT values and duration of symptom onset, for all three diagnostic

modalities (Figure 2). Comparison of CT values for the paired NP, saliva and buccal swabs are shown

in Figure 3.

DISCUSSION

In this study, we have shown that saliva tests and buccal swabs were comparable to each other and

were in moderate agreement with NPS for the detection of SARS-CoV-2, with PPA between 56 and 66%

and PPV 95 to 100%. On the other hand, both saliva tests and buccal swabs performed comparably to

NPS in detecting negative cases, with an NPA of 90 to 100%. Overall, they were moderately

comparable to NPS with an OA of 69 to 74%. This paves the way for larger validation studies to support

the use of self-collected saliva tests or buccal swabs, without the risk of community spread or spread

to HCW.

Most coronaviruses are known to replicate in the epithelial cells of the respiratory tract. The viral

shedding pattern in SARS-CoV-2 has been shown to be similar to that of the influenza virus, with peak

viral shedding in the first week of illness [6, 10]. NPS has been shown to have better diagnostic

accuracy compared to oropharyngeal swab [10-12], and it has been recommended as the gold

standard diagnostic modality. However, there is emerging evidence alluding to similar detection rates

with alternative sample collection methods that may be feasible and safe, including saliva, posterior

oropharyngeal saliva, and throat washing.

Self-collected saliva offers a promising prospect for sample collection. This is due to its relative

convenience, comfort and subjective participant preference compared to the NPS. It is also less costly

and quicker to obtain [13], with the additional benefit of decreased risk of transmission to HCWs,

making it a convenient and safe means of mass testing. There is increasing evidence that the viral load

in saliva is comparable or higher than that in the nasopharynx [4, 14-16]. We have shown that the CT

values were comparable between saliva and NPS, representing a similar viral load in both samples. A

longitudinal study in Korea showed that the highest viral load was in the nasopharynx, but also

remarkably high in the saliva, and was detected in the saliva up to day 6 of hospitalization and day 9

of illness [4]. Azzi et al reported a high overall concordance rate of 97.4% between NPS and saliva, and

also showed that there were no statistically significant difference between viral loads of the two

diagnostic test for SARS-CoV-2. However, the low PPA of 66.7% may limit its suitability to replace NPS

samples [15, 17]. Our results also showed a high PPV of 95.2% compared to NPS, the current standard

as the gold standard diagnostic test. Existing studies have also shown varying PPA or concordance

rates, when comparing saliva detection rates to NPS, with reported positive concordance rates ranging

from 45.6% [14] to 94.8% [18]. The vast differences in concordance rates may be due to limitations in

sample collection. The lower PPA might also be limited by the amount and sample collection technique

of the saliva test. Moreover, considering the similar viral load between saliva and NPS, this further

supports that poor sample collection technique might be the reason leading to some saliva tests being

completely negative. Unfortunately, our study did not investigate the quality of the saliva produced.

Kojima et al observed that there were differences in positive detection rates between clinician

supervised vs unsupervised self-collected saliva tests and NPS, which further supports that collection

technique plays a big role in the positive detection rates [7]. Another possible explanation is the

duration from diagnosis to sample collection. Wyllie et al has shown that a higher percentage of saliva

samples remained positive up to 10 days after the COVID-19 diagnosis compared to NPS (81% vs

71%)[19], which is a result supported by other studies [20, 21]. Although our results show a non-

significant relationship between interval after symptom onset and sample collection, other studies

have shown a possibility that NP and saliva are most equivalent early in the illness compared to those

collected beyond the first week [22]. Not surprisingly, the presence of symptoms increased the PPA

for saliva compared to NPS (79.2%, 19/24). Overall, these findings provide supporting evidence for

recommending saliva as an alternative modality that is safer, more comfortable and convenient to

collect, and sufficiently accurate for making a clinical diagnosis.

There are very few studies evaluating the use of buccal swabs, with conflicting results between studies

[7, 22, 23]. Our results show that the buccal swab performs less accurately than NPS due to its lower

PPA rate of 56.7%. It also has a lower viral load as reflected in the significantly higher CT value obtained.

However, participants in our study ranked it as the most convenient, comfortable and preferred test.

produce saliva, such as in young children and older patients [23].

The correlation of detection rates and symptoms still remains controversial. Zou et al showed that

Thus, buccal swabs may have a role in specific populations who might not be able to spontaneously

viral load in asymptomatic patients was similar to symptomatic patients with NPS and throat swabs

[10], while Chau et al showed that viral loads were equivalent in symptomatic patients, but lower in

asymptomatic patients in saliva [24]. We showed that none of the tests showed evident association

with duration of symptom onset. However, symptomatic patients were more likely to be true positive

on both the buccal swab and saliva test.

Taken together, buccal and saliva samples have moderate agreement with NPS, and are reasonable

alternatives to the current gold standard NPS for diagnosis of COVID-19. In view of the comparable

viral load, high PPV and OA, moderate PPA, and greater patient comfort and convenience, we

recommend that the initial screening NPS be replaced with a saliva test or buccal swab for community

testing. If the result is positive, we can assume that the patient is truly SARS-CoV-2 positive, due to

their high PPV when compared to NPS. If negative, we should perform a confirmatory NPS before

discharging the patient, to mitigate the moderate PPA value to ensure they are truly COVID-negative

(Figure 4). This workflow is time and resource-saving, especially in the context of mass screening

strategies where resources, in particular HCWs, are scarce. In this context, saliva tests or buccal swabs

can easily increase testing rates due to their ease of collection, without further straining the

healthcare system. The requirement for a confirmatory NPS for negative cases combines the

sensitivity of NPS with the high NPA of buccal and saliva samples, while saving cost, minimizing

discomfort and reducing the risk of spread to the community and to HCWs.

Our study has several strengths. Firstly, we were able to obtain self-collected specimens for buccal

swab and saliva samples, testing the feasibility of widespread application in the community with saliva

tests and buccal swabs being more acceptable to patients than NPS. Secondly, we were also able to

recruit a variety of symptomatic and asymptomatic patients at various stages of their disease.

However, our study does have several limitations. Firstly, our sample size was relatively small. We

have only included patients who previously tested positive for SARS-CoV-2, limiting its generalizability

to population screening. Participants were also recruited up to a week after first testing positive for

SARS-CoV-2 PCR, thus resulting in 26.2% who were negative on all three specimen samples. We also

limited our study to the adult population. Chong et al has shown that saliva tests might not be useful

in the paediatric population [25], which might limit its use as a population screening test. Even though

the samples were self-collected, they were still conducted in the context of a healthcare setting and

under the supervision of a HCW. Thus, the performance of the tests may be overestimated. Hence,

larger validation studies need to be performed in both symptomatic and asymptomatic patients

before buccal and saliva samples can be routinely recommended in the clinical setting.

**CONCLUSION** 

Saliva and buccal swabs were comparable to each other and were in moderate agreement with NPS

for the detection of SARS-CoV-2. Both saliva and buccal swabs had greater patient preference in terms

of comfort and convenience. Primary screening for SARS-CoV-2 may be performed with a saliva or

buccal test. A negative test warrants a confirmatory NPS to avoid false negatives. Buccal swabs might

be considered in the context of specific cohorts where spontaneous saliva production might be

difficult. These self-collection methods represent feasible alternatives that could help reduce the

discomfort experienced by patients, save costs, and reduce the risk of community spread and spread

to HCWs. Larger trials should be conducted to determine the generalizability of these tests in both the

symptomatic and asymptomatic population before they could be used for large scale community

testing.

**FUNDING** 

This work was supported by the FY2020 SingHealth Duke-NUS Obstetrics & Gynaecology Academic Clinical Programme, SingHealth Duke-NUS COVID-19 Innovation Grant [01/FY2020/P2(C1)/01-A48]. JCKY received support from Singapore's Ministry of Health's National Medical Research Council CSA-SI-0008-2016.

**ACKNOWLEDGEMENTS** 

We would like to thank the patients for participating in the study. We would also like to thank the clinical research coordinators involved, Ms Ang Siew Boon and Mr Kearney Tan Jun Yao.

#### REFERENCES

- 1. Liu W, Zhang Q, Chen J, et al. Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. N Engl J Med 2020; 382(14): 1370-1.
- 2. Diseases CfPoC. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19) 2020.
- 3. Pan Y, Zhang D, Yang P, Poon LLM, Wang Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect Dis 2020; 20(4): 411-2.
- 4. Yoon JG, Yoon J, Song JY, et al. Clinical Significance of a High SARS-CoV-2 Viral Load in the Saliva. J Korean Med Sci 2020; 35(20).
- 5. Qian Y, Zeng T, Wang H, et al. Safety management of nasopharyngeal specimen collection from suspected cases of coronavirus disease 2019. International Journal of Nursing Sciences **2020**; 7(2): 153-6.
- 6. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581(7809): 465-9.
- 7. Kojima N, Turner F, Slepnev V, et al. Self-Collected Oral Fluid and Nasal Swabs Demonstrate Comparable Sensitivity to Clinician Collected Nasopharyngeal Swabs for Covid-19 Detection. medRxiv 2020: 2020.04.11.20062372.
- 8. SingHealth. Virology. Available at: <a href="https://www.sgh.com.sg/patient-care/specialties-">https://www.sgh.com.sg/patient-care/specialties-</a> services/pathology/pages/virology.aspx. Accessed 29 Sept 2020.
- 9. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 2020; 25(3).
- 10. Zou L, Ruan F, Huang M, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. New England Journal of Medicine 2020; 382(12): 1177-9.
- Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. 11. JAMA 2020; 323(18): 1843-4.
- 12. Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv **2020**: 2020.02.11.20021493.
- 13. To KKW, Yip CCY, Lai CYW, et al. Saliva as a diagnostic specimen for testing respiratory virus by a point-of-care molecular assay: a diagnostic validity study. Clin Microbiol Infect 2019; 25(3): 372-8.
- 14. Mohan Rao FAR, Fashihah S.A.H. Sabri, Nur Nadia Jamil, Rozainanee Zain, Rohaidah Hashim, Fairuz Amran, Huey Tean Kok, Md Anuar Abd Samad, Norazah Ahmad. Comparing nasopharyngeal swab and early morning saliva for the identification of SARS-CoV-2. Clinical Infectious Diseases 2020.
- 15. Iwasaki S, Fujisawa S, Nakakubo S, et al. Comparison of SARS-CoV-2 detection in nasopharyngeal swab and saliva. Journal of Infection 2020; 81(2): e145-e7.
- 16. Liu R, Yi S, Zhang J, Lv Z, Zhu C, Zhang Y. Viral Load Dynamics in Sputum and Nasopharyngeal Swab in Patients with COVID-19. J Dent Res 2020: 22034520946251.
- 17. Azzi L, Carcano G, Gianfagna F, et al. Saliva is a reliable tool to detect SARS-CoV-2. Journal of Infection 2020; 81(1): e45-e50.

- 18. Chen JH-K, Yip CC-Y, Poon RW-S, et al. Evaluating the use of posterior or pharyngeal saliva in a point-of-care assay for the detection of SARS-CoV-2. Emerging Microbes & Infections 2020; 9(1): 1356-9.
- 19. Wyllie AL, Fournier J, Casanovas-Massana A, et al. Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2. New England Journal of Medicine 2020.
- 20. Becker D, Sandoval E, Amin A, et al. Saliva is less sensitive than nasopharyngeal swabs for COVID-19 detection in the community setting. medRxiv 2020: 2020.05.11.20092338.
- 21. Williams E, Bond K, Zhang B, Putland M, Williamson DA. Saliva as a Noninvasive Specimen for Detection of SARS-CoV-2. Journal of Clinical Microbiology 2020; 58(8): e00776-20.
- 22. Mwaddah AG, Hardip Singh; Lum, Sai Guan; Marina, Mat Baki. Upper respiratory tract sampling in COVID-19. Malaysian J Pathol 2020; 42(1): 23-35.
- 23. Kam K-q, Yung CF, Maiwald M, et al. Clinical Utility of Buccal Swabs for Severe Acute Respiratory Syndrome Coronavirus 2 Detection in Coronavirus Disease 2019–Infected Children. Journal of the Pediatric Infectious Diseases Society 2020; 9(3): 370-2.
- 24. Chau NVV, Lam VT, Dung NT, et al. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. medRxiv 2020: 2020.04.27.20082347.
- 25. Chong CY, Kam K-Q, Li J, et al. Saliva is not a useful diagnostic specimen in children with Coronavirus Disease 2019. Clinical Infectious Diseases 2020.

**TABLES** 

Table 1 Baseline demographics and clinical characteristics of patients and the results of paired

nasopharyngeal, buccal and saliva test performed (n=42)

Table 2 Comparison between nasopharyngeal and buccal swab (a), and nasopharyngeal and saliva test

(b) with positive percent agreement, negative percent agreement, positive predictive value and

negative predictive value.

**Table 3** The associations between diagnostic tests and presence of symptoms

FIGURE LEGENDS

Figure 2

Nasopharyngeal swab

**Buccal swab** 

Saliva test

**FIGURES** 

Figure 1 Comparison of cycle threshold values between nasopharyngeal swab and buccal swab (A) and

between nasopharyngeal swab and saliva test (B). Error bars represent 95% confidence intervals of

the mean values. P-value was based on paired-t test.

Figure 2 The associations between cycle threshold values of nasopharyngeal, buccal and saliva tests

with duration of symptom onset. CT of nasopharyngeal swab and days: r=0.14 (p=0.485); CT of buccal

swab and days: r=0.07 (p=0.806); CT of saliva test and days: r=0.171 (p=0.471).

Figure 3 Comparison of CT value for paired nasopharyngeal, saliva and buccal swabs performed in

SARS-CoV-2 positive patients

Figure 4 Recommended clinical workflow for population screening of SARS-CoV-2

**Table 1** Baseline demographics, clinical characteristics of patients and the results of paired nasopharyngeal, buccal and saliva test and patient experience survey performed (n=42)

	Covid-19 swab								
	Nasopharyngeal Swab		b Buccal swab				Saliva test		
	Positive	Negative	р	Positive	Negative	p	Positive	Negative	р
	(n=30)	(n=12)		(n=17)	(n=25)		(n=21)	(n=21)	
Demographics									
Age in years, (mean,	43.3 (8.5)	48.2 (2.9)	0.009	42.1 (8.1)	46.5 (6.9)	0.066	42.5 (8.9)	46.9 (5.5)	0.062
SD)									
Sex			>0.950			>0.950			>0.950
Male	28 (93.3)	12 (100)		16 (94.1)	24 (96.0)		20 (95.2)	20 (95.2)	
Female	2 (6.7)	0		1 (5.9)	1 (4.0)		1 (4.8)	1 (4.8)	
Race			>0.950			0.029			0.138
Indian	13 (43.3)	5 (41.7)		3 (17.6)	15 (60.0)		6 (28.6)	12 (57.1)	
Chinese	6 (20.0)	2 (16.7)		5 (29.4)	3 (12.0)		6 (28.6)	2 (9.5)	
Others	11 (36.6)	5 (41.7)		9 (52.9)	7 (28.8)		9 (42.9)	7 (33.3)	

	Covid-19 swab								
	Nasopharyngeal Swab			Buccal swab			Saliva test		
	Positive	Negative	р	Positive	Negative	p	Positive	Negative	р
	(n=30)	(n=12)		(n=17)	(n=25)		(n=21)	(n=21)	
Clinical characteristics									
Symptoms			0.069			0.013			0.001
No	6 (20.0)	6 (50.0)		1 (5.9)	11 (44.0)		1 (4.8)	11 (52.4)	
Yes	24 (80.0)	6 (50.0)		16 (94.1)	14 (56.0)		20 (95.2)	10 (47.6)	
Symptoms onset, days	3.5 (1.0-5.0)	1.0 (0-	0.524	4.0 (2.0-5.0)	2.0 (0-6.0)	0.253	4.0 (3.0-8.0)	0 (0-3.5)	0.013
(median, 25 <sup>th</sup> -75 <sup>th</sup> )		7.0)							
Participant Experience									
Most <b>comfortable</b> to co	llect	0 (0)		25 (5	9.5)		17 (4	0.5)	
Most <b>convenient</b> to coll	ect	0 (0)		25 (5	9.5)		17 (4	0.5)	
Ranked as most <b>prefera</b>	ble 1	. (2.4)		25 (5	9.5)		16 (3	8.1)	

P-value was based on independent t-test or Mann-Whitney test for continuous variables, as appropriately, and fisher's exact test for categorical variables.

SD, standard deviation.

Table 2 Comparison between nasopharyngeal and buccal swab (a), and nasopharyngeal and saliva test (b) with positive percent agreement, negative percent agreement, positive predictive value and negative predictive value.

		Nasophary	ngeal swab	
		Positive	Negative	-
(a) Buccal	Positive	17	0	Positive predictive value = 100%
swab	Negative	13	12	Negative predictive value = 48.0%
		Positive Percent	Negative Percent	Overall Agreement = 69.0%
		Agreement = 56.7%	Agreement = 100%	
		Nasophary	ngeal swab	
		Positive	Negative	-
(b) Saliva	Positive	20	1	Positive predictive value = 95.2%
test	Negative	10	11	Negative predictive value = 52.4%
		Positive Percent	Negative Percent	Overall Agreement = 73.8%
		Agreement = 66.67%	Agreement = 91.7%	

Table 3 The associations between diagnostic tests and presence of symptoms

Buccal swa	b vs. Nasophary	ngeal swab	Saliva test vs. Nasopharyngeal swab			
Sym	ptoms		Sym			
No	Yes	p	No	Yes	р	
1 (8.3)	16 (53.3)	0.017	1 (8.3)	19 (63.3)	0.004	
0	0		0	1 (3.3)		
5 (41.7%)	8 (26.7)		5 (41.7)	5 (16.7)		
6 (50.0)	6 (20.0)		6 (50.0)	5 (16.7)		
	No 1 (8.3) 0 5 (41.7%)	Symptoms  No Yes  1 (8.3) 16 (53.3)  0 0  5 (41.7%) 8 (26.7)	No Yes p  1 (8.3) 16 (53.3) 0.017  0 0  5 (41.7%) 8 (26.7)	Symptoms         Sym           No         Yes         p         No           1 (8.3)         16 (53.3)         0.017         1 (8.3)           0         0         0           5 (41.7%)         8 (26.7)         5 (41.7)	Symptoms         Symptoms           No         Yes         p         No         Yes           1 (8.3)         16 (53.3)         0.017         1 (8.3)         19 (63.3)           0         0         0         1 (3.3)           5 (41.7%)         8 (26.7)         5 (41.7)         5 (16.7)	

P-value was based on Fisher's exact test.

Figure 1 Comparison of cycle threshold values between nasopharyngeal swab and buccal swab (A) and between nasopharyngeal swab and saliva test (B). Error bars represent 95% confidence intervals of the mean values. P-value was based on paired-t test.




Figure 2 The associations between cycle threshold values of nasopharyngeal, buccal and saliva tests with duration of symptom onset. CT of nasopharyngeal swab and days: r=0.14 (p=0.485); CT of buccal swab and days: r=0.07 (p=0.806); CT of saliva test and days: r=0.171 (p=0.471).





Figure 3 Comparison of CT value for paired nasopharyngeal, saliva and buccal swabs performed in SARS-CoV-2 positive patients



Saliva Swab PCR False negative (red): 10

**Buccal Swab PCR** False negative (red): 13

Figure 4 Recommended clinical workflow for population screening of SARS-CoV-2

